As per the lab reports, no infectious virus was detected after 30 seconds of using the ointment
A pharmaceutical company based in USA has been successful in testing a Food and Drug Administration (FDA) approved ointment as a first line of defence in killing the deadly coronavirus. The ointment is already available in the market and doesn't need any medical prescriptions to buy it.
Scientists who tested the over the counter (OTC) FDA approved ointment said that it has proven to prevent, treat and kill viral infections including coronavirus.
“As per the lab report states, no infectious virus was detected after 30 seconds of T3X treatment,” said the pharmaceutical company in a statement.
“We believe this will be a breakthrough that will reduce the likelihood of becoming infected with coronavirus through the nose, which is where most cases are contracted,” said Dr Brian Huber, CEO and founder of Advanced Penetration Technology.
“This is a big deal. It is the type of protection a lot of people have been hoping for and could be a first line of defence against the COVID virus. It is a powerful and effective layer of prevention,” Huber added.
Huber revealed the details after the pharmaceutical company published the results of an independent laboratory test of a topical medical formulation that mitigates coronavirus from entering the body through the nasal passages, thereby significantly reducing the chances of people getting infected with the deadly virus.
A fresh study by Massachusetts Institute of Technology (MIT) revealed that humans get infected with COVID-19 and other viruses primarily through the nose. However, there are also chances of the virus entering the body eyes and the mouth.
“T3X is an FDA registered, over-the-counter formulation, which means that no prescription is needed. It is easy to use and can be self-administered without the assistance of medical personnel or technicians,” the company said. A London-based research laboratory, Virology Research Services Ltd, evaluated the anti-viral impact of the product, named APT™ T3X, against Corona Virus (NL63) and Influenza A virus and concluded that it is a highly effective formulation against coronavirus, it said. The research concludes that APT™ T3X effectively neutralises viral infectivity within seconds. The anti-viral efficacy supports the topical intranasal use of APT™ T3X to decrease the viral load of exposure. “Under the conditions tested, APT T3X displays a 99.9% virucidal activity against human coronavirus NL63,” the company further clarified in its statement.
The over the counter FDA approved ointment was initially developed eight years ago for bacterial infections but its formula also provided relief against powerful fungal and viral infections. The ointment also has no documented side effects on humans.